Skip to main content
AMLX
NASDAQ Life Sciences

Amylyx Q2 Loss Wider Than Expected, But Avexitide Phase 3 Data Looms

Tom Rudovsky · Reported by Reuters
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$21.61
Mkt Cap
$2.429B
52W Low
$7.48
52W High
$22.28
52W Position info
189% above low
Off High info
3.0% below high
Rel. Volume info
1.1× avg
Market data snapshot near publication time

AMLX has more than doubled off its 52-week low of $7.48.

Summary

Amylyx posted a Q2 loss of $0.39 per share, missing the $0.36 consensus, on higher SG&A costs tied to legal expenses and commercial prep. The miss is modest, but the real story is the pipeline: the final patient visit in the pivotal Phase 3 LUCIDITY trial for avexitide is complete, with topline data due in late August or early September. Cash of $250.8M funds operations into 2028, well past the expected 2027 launch if approved. The stock is near its 52-week high, so the market is already pricing in avexitide success — any data disappointment would hit hard. This follows a Q1 report that also showed a wider loss but highlighted Phase 3 enrollment completion.

At the time of this announcement, AMLX was trading at $21.61 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.4B. The 52-week trading range was $7.48 to $22.28. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.


Price Chart

Share this article

Copied!

AMLX - Latest Insights

AMLX
Nov 05, 2026, 7:04 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $30.00
Real-time Price: $27.15 info
Change: -$2.85 (-10%) info
Market Cap: $3.422B info
AMLX
Sep 08, 2026, 4:54 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $33.88
Real-time Price: $27.15 info
Change: -$6.73 (-20%) info
Market Cap: $3.422B info
AMLX
Aug 20, 2026, 5:28 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $39.71
Real-time Price: $27.15 info
Change: -$12.56 (-32%) info
Market Cap: $3.422B info
AMLX
Aug 20, 2026, 5:27 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $39.71
Real-time Price: $27.15 info
Change: -$12.56 (-32%) info
Market Cap: $3.422B info
AMLX
Aug 19, 2026, 11:06 PM EDT
Source: BusinessWire
Importance Score:
9
Price at Filing: $38.45
Real-time Price: $27.15 info
Change: -$11.30 (-29%) info
Market Cap: $3.422B info